Observational study on patients with nonalcoholic fatty liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on patients diagnosed with nonalcoholic fatty liver disease (NAFLD) and aims to categorize them into NAFLD and nonalcoholic steatohepatitis (NASH) groups. Researchers will collect various clinical examination indexes, including liver enzyme levels and triglyceride content, to assess the condition and prognosis of the patients. Additionally, biological samples such as serum, feces, urine, and liver tissue will be collected for future testing. The study does not involve any additional interventions or treatments for the participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1\. patients diagnosed with nonalcoholic fatty liver disease

Exclusion Criteria:

1. patients suspected of excessive alcohol consumption
2. malignant tumors, dementia, active tuberculosis, AIDS, organ failure, pregnancy or breastfeeding, etc cannot cooperate with the investigation
3. incomplete data such as HBV serological results and abdominal ultrasound results
4. patients who refuse to sign informed consent

Where it's running

• Department of Infectious Disease, Xiangya Hospital, Central South University
  Changsha, Hunan, China Recruiting

Study contacts

• Study coordinator: Yan Huang
• Email: ganrankedrhyan@163.com
• Phone: +86 13874854142

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining genetics, blood, urine, and stool data to predict complications of metabolic syndrome

  The team will try combining genetic, blood, urine, and stool data to see if patterns predict complications in adults with or without metabolic syndrome.

  Recruiting Chang Gung Memorial Hospital · Taoyuan · NCT07248371

• ERCG (clip-and-loop endoscopic gastric reduction) versus optimized lifestyle for weight loss

  This trial will test whether ERCG, a sutureless endoscopic clip-and-loop procedure that reduces stomach volume, helps Chinese adults with BMI 24.0–37.4 kg/m² lose more weight than an optimized lifestyle program.

  Recruiting Beijing 302 Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07237750

• New MRI methods to measure metabolism and predict outcomes in metabolic-associated fatty liver disease

  This project tests whether new MRI techniques can measure body metabolism and help predict disease status and prognosis for people with metabolic-associated fatty liver disease.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07149571

• Low‑methoxy pectin for inflammation, gut microbiome, and metabolic health in MASLD

  This tests whether taking daily low‑methoxy pectin for six weeks can reduce inflammation and improve gut bacteria and metabolic markers in adults with MASLD.

  Recruiting at 3 sites University of Nottingham · Nottingham, United Kingdom and 2 other locations · NCT07093346

• Effects of Henagliflozein on liver fat in patients with diabetes and fatty liver disease

  This study is testing if a new diabetes medication called Henagliflozein can help reduce liver fat in people with type 2 diabetes and fatty liver disease.

  Recruiting Phase 4 Zhujiang Hospital · Guangzhou, Guangdong · NCT06449833

• Antiviral therapy for chronic hepatitis B with nonalcoholic fatty liver disease

  This study is testing if a new antiviral treatment can help people with chronic hepatitis B and fatty liver disease clear the virus better than the standard medication.

  Recruiting at 5 sites Phase 4 First Affiliated Hospital of Wenzhou Medical University · Ningbo and 4 other locations · NCT06368882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.